There are approx 1.6 million new lung cancer cases each year. Of these, about 15% are in the US. So, ROW is approx is 1.37 million cases. 90% are NSCLC and 4%, or almost 50,000 are ALK+. So, purely on the basis of the number of new cases, non-US represents a significant potential market.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.